Table 3

Patient characteristics associated with specific initial voriconazole troughsa

Patient characteristic% of patients with an initial voriconazole trough concnb of:P value% of patients with an initial voriconazole trough concn of:P value% of patients with an initial voriconazole trough concn of:P value
≤1 μg/ml (n = 33)>1 μg/ml (n = 60)≤1.5 μg/ml (n = 37)>1.5 μg/ml (n = 56)≤4 μg/ml (n = 79)>4 μg/ml (n = 14)
Age ≥ 60 yrs (n = 53)23 (12/53)77 (41/53)0.00430 (16/53)70 (37/53)0.0377 (41/53)23 (12/53)0.02
Age < 60 yrs (n = 40)52.5 (21/40)47.5 (19/40)52.5 (21/40)47.5 (19/40)95 (38/40)5 (2/40)
Cystic fibrosis (n = 12)67 (8/12)33 (4/12)0.0275 (9/12)25 (3/12)0.01100 (12/12)0 (0/12)0.20
Other disease (n = 81)31 (25/81)69 (56/81)35 (28/81)65 (53/81)83 (67/81)17 (14/81)
  • a There were no significant associations between initial voriconazole troughs and patients' sex, race, body mass index, lung diseases other than cystic fibrosis, presence of underlying liver disease, route of voriconazole administration, or receipt of concomitant acid suppressive therapy (data not shown). The P values result from a comparison of values for the patients with the lower trough concentration compared to the patients with the higher trough concentration.

  • b The values in parentheses are the number of patients with the initial voriconazole trough concentration to the total number of patients.